Breaking News, Collaborations & Alliances

Avacta, Daewoong Partner with AffyXell Therapeutics

To utilize Affimer proteins in next generation cell and gene therapies

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Avacta Group has signed a collaboration and license agreement with AffyXell Therapeutics, the recently established joint venture with Daewoong Pharmaceutical, to develop Affimer proteins to be used by AffyXell for the generation of new cell and gene therapies.   Avacta and AffyXell will now work together to develop Affimer proteins against a range of targets which, when produced by mesenchymal stem cells (MSCs), are intended to inhibit inflammatory and autoimmune pathways and improve the overa...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters